Price history
¥750Latest+24.4%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 19
PER
585.72How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
5.92How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
1.0%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥30bnShare price × number of shares. The value of the entire company.Equity ratio
87.0%The proportion of assets funded by money that does not have to be repaid.Operating margin
7.7%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
5.0%The average annual growth in sales over the past three years.What to watch next
Reimbursement coverage and launch of expanded indications for the autologous cultured cartilage product Jack in knee osteoarthritis, together with the ramp-up in patient cases as the number of contracted facilities increases
2026/2027 (dependent on the staged expansion plan described)Impact HighLikelihood Medium
Post-reimbursement adoption and stabilization of sales volumes for Jasmine, an autologous cultured epidermis containing melanocytes, including operational activity associated with pricing and indication management
2025〜2026Impact MediumLikelihood Medium
Completion of clinical development, submission for approval, and launch of Allo-JaCE03, an allogeneic cultured epidermis product (targeted for the fiscal year ending March 2027)
2026〜2027Impact HighLikelihood Low
Progress in facility and equipment expansion and personnel development tied to the award of regenerative-medicine CDMO subsidies, together with growth in contract projects
2025–2026 (subject to the development of specific investment plans)Impact MediumLikelihood Medium
Growth in overseas orders for the Labsite business, supported by compliance with international standards (OECD/ISO), including preparations to establish a European base and expansion into India
2026〜Impact MediumLikelihood Low
The contractual terms of the Teijin Group collaboration in the regenerative-medicine contract-services business, including use licenses and outsourcing agreements, milestones and royalties, and their linkage to actual results
Ongoing (depending on annual and contractual progress)Impact MediumLikelihood Medium
What to watch next
Who owns itTop holders total 72.5%
Listed holders 72.5%Everyone else 27.5%
TEIJIN LIMITED57.71%
NIDEC CORPORATION10.40%
Maeda Yoko (前田陽子)0.84%
Gomi Daisuke (五味大輔)0.81%
小澤洋介0.71%
J-TEC従業員持株会0.60%
サーラエナジー株式会社0.45%
上田八木短資株式会社0.36%
2 other listed holders0.62%
| Holder | Ownership (%) |
|---|---|
| TEIJIN LIMITED | 57.71 |
| NIDEC CORPORATION | 10.40 |
| Maeda Yoko (前田陽子) | 0.84 |
| Gomi Daisuke (五味大輔) | 0.81 |
| 小澤洋介 | 0.71 |
| J-TEC従業員持株会 | 0.60 |
| サーラエナジー株式会社 | 0.45 |
| 上田八木短資株式会社 | 0.36 |
| 2 other listed holders | 0.62 |
This company's documents
Filings
Timely disclosures
- 2026-07-31(Correction) Partial correction to the "First-Quarter Financial Results Presentation for the Fiscal Year Ending March 2027"
- 2026-07-30Earnings Presentation Materials for the First Quarter of the Fiscal Year Ending March 2027
- 2026-07-30Q1 Financial Results for the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)
- 2026-06-19Notice of Personnel Changes
- 2026-06-19Matters Concerning Controlling Shareholders
- 2026-06-19Notice Regarding the Establishment of a Subsidiary in the Federal Republic of Germany
- 2026-05-28Materials for the 28th Annual General Meeting of Shareholders for Fiscal 2026 (Notes to Non-Consolidated Financial Statements)
- 2026-05-28Notice of Convocation of the 28th Annual General Meeting of Shareholders for 2026
6 more
- 2026-05-01(Correction) Partial correction to "Matters Concerning the Business Plan and Growth Potential"
- 2026-05-01Business Plan and Growth Potential
- 2026-05-01Earnings Presentation Materials for the Fiscal Year Ending March 2026
- 2026-05-01Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated)
- 2026-04-24Notice Regarding the Recognition of an Impairment Loss on Investment Securities (Extraordinary Loss) and the Revision of Full-Year Earnings Forecast
- 2026-03-26Application for marketing approval of the world's first dry allogeneic cultured epidermis